The present invention discloses an antibody drug conjugate that targets MSLN.The presentinvention also disclosed a method of making the antibody drug conjugate (ADC).The presentinvention further discloses a novel MSLN antibody or a functional fragmentthereof comprisingengineered heavy and light chains.